Therapeutic DLL4 binding proteins
US8623358B2 · kind B2 · utility
10Cited by
66References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2010 |
| Grant date | Jan 7, 2014 |
| Priority date | — |
| Expiry date | Sep 8, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.